Bausch+Lomb Results Presentation Deck
3Q22 Highlights: Organic Revenue Growth 1.2 in All Three Segments.
Despite Inflation and FX Headwinds
Bausch + Lomb
3Q22 vs. 3Q21
(1%) 3Q22 Reported Revenue
5% 3Q22 Organic Revenue ¹,2
5%
3Q22 Constant Currency¹
Ophthalmic
Pharmaceuticals
18%
Surgical
18%
BAUSCH + LOMB
Vision Care
64%
Continued
Momentum in
Key Portfolios
+14%
reported revenue growth
Ocuvite® + PreserVision®
PreserVision® has ~95%
market share in U.S.³
+14%
organic revenue growth ¹,2
in surgical implantables,
driven by premium and
standard IOLS
Investing in
Categories Growing
Faster Than Market
4. IQVIA NSP.
5. Clarivate. See Slide 1 for further information on forward-looking statements.
-49%
U.S. weekly market share for
Lumify® in Redness Reliever
Category³; strong early
launch in Canada
~24%
CAGR (2016-2021)4
U.S. prescription dry eye
market; expect double digit
growth 2021-20275
NOV03 PDUFA Date
June 2023
1.
This is a non-GAAP measure or ratio. See Slide 2 and Appendix for further information on non-GAAP measures and ratios.
2. Organic revenue growth/change, a non-GAAP ratio, is defined as a change on a period-over-period basis in revenues on a constant currency basis (if applicable) excluding the impact of acquisitions, divestitures and discontinuations,
3. IRI Panel Omnichannel.
Expanding Into
New Product
Categories
Entered into an exclusive
European distribution
agreement for MIMSⓇ
minimally invasive surgical
procedure for treatment of
glaucoma
LUXSMART
SMART
LuxSmart TM Premium IOL
launched in 19 countries
7View entire presentation